Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2019-09-23
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the efficacy, dose response, and safety of M52951
in participants with Rheumatoid Arthritis (RA), and to consider a dose to took forward into
Phase III development.